Will Medicare’s 2026 Rule Shift and Amedisys Integration Strengthen Pennant Group’s (PNTG) Narrative?

Simply Wall St.12-04

Earlier this week, Truist Securities upgraded The Pennant Group to a buy rating, highlighting solid operating trends, strong sector demand, and reduced reimbursement risk following a less restrictive ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2588752029?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6033000-choice2-main-header/1585186569462","is_english":true,"pubTime":"2025-12-04 03:27","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2588752029","market":"sg","top_or_hot":-1,"title":"Will Medicare’s 2026 Rule Shift and Amedisys Integration Strengthen Pennant Group’s (PNTG) Narrative?","media":"Simply Wall St.","content":"<div>\n<p>Earlier this week, Truist Securities upgraded The Pennant Group to a buy rating, highlighting solid operating trends, strong sector demand, and reduced reimbursement risk following a less restrictive ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nasdaq-pntg/pennant-group/news/will-medicares-2026-rule-shift-and-amedisys-integration-stre\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Will Medicare’s 2026 Rule Shift and Amedisys Integration Strengthen Pennant Group’s (PNTG) Narrative?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWill Medicare’s 2026 Rule Shift and Amedisys Integration Strengthen Pennant Group’s (PNTG) Narrative?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-12-04 03:27 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/healthcare/nasdaq-pntg/pennant-group/news/will-medicares-2026-rule-shift-and-amedisys-integration-stre><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Earlier this week, Truist Securities upgraded The Pennant Group to a buy rating, highlighting solid operating trends, strong sector demand, and reduced reimbursement risk following a less restrictive ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nasdaq-pntg/pennant-group/news/will-medicares-2026-rule-shift-and-amedisys-integration-stre\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1093756168.USD","symbol_name":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","start_time":0,"source_url":"https://simplywall.st/stocks/us/healthcare/nasdaq-pntg/pennant-group/news/will-medicares-2026-rule-shift-and-amedisys-integration-stre","article_id":"2588752029","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6033000-choice2-main-header/1585186569462"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nasdaq-pntg/pennant-group/news/will-medicares-2026-rule-shift-and-amedisys-integration-stre","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2588752029","pubTimestamp":1764790063,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Earlier this week, Truist Securities upgraded The Pennant Group to a buy rating, highlighting solid operating trends, strong sector demand, and reduced reimbursement risk following a less restrictive 2026 Medicare home health rule.\nAnalysts also pointed to Pennant’s smooth integration of 54 acquired Amedisys locations as a key factor supporting its operational and earnings outlook.\nWith that backdrop, we’ll now explore how the favorable 2026 Medicare rule update may affect Pennant’s broader...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","BK4185":"保健护理机构","BK4196":"保健护理服务","PNTG":"The Pennant Group, Inc.","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","AMED":"阿米斯医疗"},"translate_title":"Medicare 2026年规则转变和Amedisys整合是否会加强Pennant Group(PNTG)的叙述？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PNTG":1.5,"AMED":1.5},"content_text":"Earlier this week, Truist Securities upgraded The Pennant Group to a buy rating, highlighting solid operating trends, strong sector demand, and reduced reimbursement risk following a less restrictive 2026 Medicare home health rule. Analysts also pointed to Pennant’s smooth integration of 54 acquired Amedisys locations as a key factor supporting its operational and earnings outlook. With that backdrop, we’ll now explore how the favorable 2026 Medicare rule update may affect Pennant’s broader investment narrative. Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 36 best rare earth metal stocks of the very few that mine this essential strategic resource.AdvertisementPennant Group Investment Narrative RecapTo own Pennant Group, you generally need to believe in long term demand for home health and senior living, and in Pennant’s ability to scale efficiently through acquisitions. The recent Truist upgrade and less restrictive 2026 Medicare home health rule directly soften one of the biggest near term risks from reimbursement cuts, while integration and labor costs remain key swing factors for results over the next few years. Among recent updates, Pennant’s Q3 2025 results and reiterated full year 2025 revenue guidance of US$911.4 million to US$948.6 million stand out alongside the Medicare rule news. Together, they frame a story where growth from acquisitions, including the Amedisys locations, is showing up in reported numbers, but investors still need to watch how higher debt capacity and margin pressures interact with evolving reimbursement rules. However, investors should also be aware that Pennant’s heavy reliance on government payers means future policy shifts could... Read the full narrative on Pennant Group (it's free!)Pennant Group's narrative projects $1.2 billion revenue and $59.3 million earnings by 2028. This requires 13.6% yearly revenue growth and a roughly $32.5 million earnings increase from $26.8 million today.Uncover how Pennant Group's forecasts yield a $33.60 fair value, a 15% upside to its current price.Exploring Other PerspectivesPNTG Community Fair Values as at Dec 2025 Five members of the Simply Wall St Community currently estimate Pennant’s fair value between US$18.33 and US$69.53, reflecting very different expectations. Against that backdrop, the eased 2026 Medicare rule helps some concerns, but reimbursement dependence and integration execution still shape how Pennant’s performance could unfold, so it is worth comparing several viewpoints before deciding what the stock is worth.Explore 5 other fair value estimates on Pennant Group - why the stock might be worth over 2x more than the current price!Build Your Own Pennant Group NarrativeDisagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.A great starting point for your Pennant Group research is our analysis highlighting 3 key rewards that could impact your investment decision.Our free Pennant Group research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Pennant Group's overall financial health at a glance.Contemplating Other Strategies?Our daily scans reveal stocks with breakout potential. Don't miss this chance:These 12 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch.AI is about to change healthcare. These 30 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.Trump has pledged to \"unleash\" American oil and gas and these 22 US stocks have developments that are poised to benefit.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2588752029","isCrawlerRequest":true}